Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
64,967,756
-
Total 13F shares
-
19,782,677
-
Share change
-
+621,072
-
Total reported value
-
$337,098,000
-
Price per share
-
$17.04
-
Number of holders
-
47
-
Value change
-
+$9,908,694
-
Number of buys
-
24
-
Number of sells
-
20
Institutional Holders of Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) as of Q2 2021
As of 30 Jun 2021,
Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,782,677 shares.
The largest 10 holders included
NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Sofinnova Investments, Inc., RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Pivotal bioVenture Partners Investment Advisor LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CHI Advisors LLC, BlackRock Inc., and Rock Springs Capital Management LP.
This page lists
47
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.